- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01001845
Comparative Effects of Milk Thistle Extract With Vitamin-E in Hemodialysis Patients
Comparative Effects of Milk Thistle Extract With Vitamin-E on Oxidative Stress Biomarkers in Hemodialysis Patients
For end-stage renal disease (ESRD) patients, cardiovascular disease remains the single most common cause of excess morbidity and mortality. Among the examined nontraditional risk factors, an increase in oxidative stress as well as inflammation are postulated to contribute to excessive cardiovascular risk in this population.
Flavonoids are naturally occurring substances that possess various pharmacological actions and therapeutic applications. Some due to their phenolic structures have antioxidant effect and inhibit free radical-mediated processes, as well as anti-inflammatory effects. Silymarin,a mixture of three isomeric flavonolignans, is isolated from milk thistle (Silybum marianum) seeds, and is proven to have anti-oxidant, anti-inflammatory, cell regenerating, and antifibrotic action.
In this study, the effect of silymarin on oxidative stress and inflammation (2 major risk factors for cardiovascular morbidity and mortality in hemodialysis patients)is evaluated, and compared to vit E, a well known antioxidant.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Fars
-
Shiraz, Fars, Iran, Islamic Republic of, 71345
- Nemazi hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All hemodialysis patients age 18-60
- On hemodialysis for over 3 months, 3 times a week, and for 4 hours each time
- Signed informed consent
Exclusion Criteria:
- Heart Failure NYHA Class III or IV
- Recent MI (within 1 year)
- Use of anti-oxidant supplements: N-acetyl-cystein, Omega 3, Vit C, Vit E, green tea, soy extracts, pomegranate extract, grape extract..
- Hepatitis B or C
- Active Infection
- Psychiatric illness
- Active malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Lifestyle counseling
|
|
Active Comparator: vit E
200mg 2 times per day for 3 weeks
|
200 mg twice daily for 3 weeks
|
Experimental: Milk Thistle extract
1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
|
1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
|
Experimental: vit E + Milk Thistle Extract
200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
|
200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
RBC Glutathion Peroxidase level
Time Frame: 3 weeks
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma malondialdehyde
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Investigators
- Study Director: Ghazal Vessal, PharmD, PhD, Shiraz University of Medical Sciences, Faculty of Pharmacy
- Principal Investigator: Bahram Shahriari, MD, shiraz University of medical sciences
- Study Chair: Jamshid Roozbeh, MD, Nephrology Urology Research Center, Shiraz University of Medical Sciences
- Principal Investigator: masoumeh Akmali, PhD, shiraz University of medical sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 53001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis
-
National Taiwan University HospitalCompletedHemodialysis Complication | Hemodialysis-Induced SymptomTaiwan
-
Ain Shams UniversityCompleted
-
Imperial College Healthcare NHS TrustCompletedHemodialysisUnited Kingdom
-
Lawson Health Research InstituteUnknown
-
Tufts Medical CenterWithdrawn
-
Federico II UniversityUnknown
-
Hospital Clinic of BarcelonaSocietat Catalana de NefrologiaCompleted
-
Osaka UniversityCompleted
-
Chinese PLA General HospitalWithdrawn
Clinical Trials on vit E
-
University Hospital, MontpellierHospital Clinical Research Project 2010; Association Amis FSH France; FSH Dutch...CompletedFacioscapulohumeral Muscular DystrophyFrance
-
Benha UniversityZagazig University; Hawaa Fertility CenterCompleted
-
University of Santiago de CompostelaCompletedHead and Neck Cancer | Oral Cancer | Oral Mucositis | Osteoradionecrosis | Hyposalivation | Osteonecrosis Due to Drugs, Jaw | Osteonecroses, BisphosphonateSpain
-
Tanta UniversityActive, not recruitingNon-alcoholic SteatohepatitisEgypt
-
Sun Yat-sen UniversityRecruitingCongenital CataractChina
-
Benha UniversityEl Galaa Teaching HospitalUnknownInfertility, FemaleEgypt
-
Vifor (International) Inc.FortreaCompletedSickle Cell DiseaseUnited States, France, Greece, Lebanon, United Kingdom
-
Tanta UniversityRecruitingHyperuricemia | Non Alcoholic SteatohepatitisEgypt
-
PepsiCo Global R&DFood and Nutrition Research Institute, PhilippinesCompleted
-
Vifor (International) Inc.Labcorp Drug Development IncWithdrawnBeta-ThalassemiaUnited States, Bulgaria, Israel